Solid Biosciences to Host First Quarter 2021 Financial Results and Business Update Call on May 14, 2021

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced it will release its first quarter 2021 financial results before the market opens on May 14, 2021. A conference call will be held at 8:30 a.m. ET to discuss the financial results and recent business updates. The event can be accessed via a live webcast on the company's website, with an archived version available afterward. Solid Biosciences focuses on developing therapies for Duchenne muscular dystrophy, primarily through its lead gene therapy candidate, SGT-001.

Positive

• Scheduled release of Q1 2021 financial results indicates transparency and communication with investors.

Negative

• None.

CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2021 financial results before the market opens on Friday, May 14, 2021. Management will host a conference call on the same date beginning at 8:30 a.m. ET to discuss the Company’s financial results and recent business developments.

A live webcast of the call will be available on the Company's website at www.solidbio.com under the “News & Events” tab in the Investor Relations section, or by clicking here. Participants may also access the call, by dialing 866-763-0341 for domestic callers or 703-871-3818 for international callers, referencing conference ID# 4772539.

The archived webcast will be available in the “News and Events” section of the Company's website.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com

FAQ

When will Solid Biosciences release its Q1 2021 financial results?

Solid Biosciences will release its Q1 2021 financial results on May 14, 2021.

What time is the Solid Biosciences conference call?

The conference call for Solid Biosciences will begin at 8:30 a.m. ET on May 14, 2021.

How can I access the Solid Biosciences conference call?

The Solid Biosciences conference call can be accessed via a live webcast on their website or by dialing the provided phone numbers.

What is Solid Biosciences focused on developing?

Solid Biosciences is focused on developing therapies for Duchenne muscular dystrophy, particularly its lead gene therapy candidate, SGT-001.